



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)
Total Number of Pages in This Submission **111**

| | |
|------------------------|------------|
| Application Number | 10/759,740 |
| Filing Date | 01/16/2004 |
| First Named Inventor | Yinghe Hu |
| Art Unit | 1646 |
| Examiner Name | |
| Attorney Docket Number | P1125US00 |

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
 - ☐ Fee Attached
- ☐ Amendment / Reply
 - ☐ After Final
 - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
 - ☐ Certified Copy of Priority Document(s)
 - ☐ Reply to Missing Parts/Incomplete Application
 - ☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
 - ☐ Petition to Convert to a Provisional Application
 - ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____
 - ☐ Landscape Table on CD

- ☐ After Allowance Communication to TC
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) (please identify below):
Return Postcard Receipt
References AA - AK

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | | | |
|--------------|--|----------|--------|
| Firm | Genomics Institute of the Novartis Research Foundation | | |
| Signature | | | |
| Printed Name | Hugh Wang | | |
| Date | April 14, 2005 | Reg. No. | 47,163 |

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

| | | | |
|-----------------------|------------------|------|---------|
| Signature | | | |
| Typed or printed name | Michelle Fecteau | Date | 4/20/05 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450, on 4/20/05

Genomics Institute of the Novartis Research Foundation

Michelle K. Fecteau
Michelle K. Fecteau

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Customer No.: 29490

Yinghe Hu et al.

Examiner:

Application No.: 10/759,740

Art Unit: 1646

Filed: January 16, 2004

For: UNIVERSAL G-PROTEIN COUPLED
RECEPTOR REPORTER
CONSTRUCTS

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR
§ 1.97 AND § 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir,

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressively considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97 (g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 501885. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Hugh Wang', with a stylized, flowing script.

Hugh Wang, Reg. No. 47,163

Customer No. 29490

Genomics Institute of the Novartis Research Foundation

10675 John J. Hopkins Drive

San Diego, CA 92121

858-812-1539 phone

858-812-1909 fax

PTO/SB/08a (08-03)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

| | |
|------------------------|------------|
| Application Number | 10/759,740 |
| Filing Date | 01/16/2004 |
| First Named Inventor | Yinghe Hu |
| Art Unit | 1646 |
| Examiner Name | |
| Attorney Docket Number | P1125US00 |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| | AA | FRIEDMAN, et al. Processing of Prothyrotropin-Releasing Hormone (Pro-TRH) by Bovine Intermediate Lobe Secretory Vesicle Membrane PC1 and PC2 Enzymes. Endocrinology, 1995. Vol. 136, No. 10, Pages 4482-4472. | |
| | AB | NILLNI, et al. Posttranslational Processing of Progrowth Hormone-Releasing Hormone. Endocrinology, 1999. Vol. 140, No. 12, p. 5817-5827. | |
| | AC | MACDONALD, et al. Posttranslational Processing of Alpha-, Beta-, and Gamma-Preprotachykinins. The Journal of Biological Chemistry, 1988. Vol. 263, No. 29, Issue of October 15, p. 15176-15183. | |
| | AD | SCHANER, et al. Processing of Prothyrotropin-releasing Hormone by the Family of Prohormone Convertases. The Journal of Biological Chemistry, 1997, Vol. 272, No. 32, Issue of August 8, p. 19958-19968. | |
| | AE | HUYNH, Hung. Post-transcriptional and post-translational regulation of insulin-like growth factor binding protein-3 and -4 by insulin-like growth factor-I in uterine myometrial cells. Growth Hormone & IGF Research 2000, Vol. 10, p. 20-27. | |
| | AF | HOOK, et al. Production of Radiolabeled Neuropeptide Precursors by in vitro Transcription and Translation, Pept. Res. 9(4): pages 183-187, 1996. | |
| | AG | FITZGERALD et al., Analyt. Biochem. 275: 54-61, 1999 | |
| | AH | WHITE et al. Evaluation of the Effectiveness of DNA-Binding Drugs to Inhibit Transcription Using the c-fos Serum Response Element as a Target. Biochemistry, Vol. 39, pages 12262-12273, 2000. | |
| | AI | SHO et al. Novel Roles of Specific Isoforms of Protein Kinase C in Activation of the c-fos Serum Response Element. Molecular and Cellular Biology, Feb. 1999, pages 1313-1324. | |
| | AJ | SEALY et al. Regulation of the c-fos Serum Response Element by C/EBP β . Molecular and Cellular Biology, Mar. 1997, pages 1744-1755. | |
| | AK | JIANG et al. Generation of a bioactive neuropeptide in a cell-free system. Analytical Chemistry, 316, 2003, pages 34-40. | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.